spacer
home > ict > summer 2019 > the service model dichotomy
PUBLICATIONS
International Clinical Trials

The Service Model Dichotomy





In the context of progressive and steady economic growth, sponsors and CROs are continually looking for the right outsourcing models to sustain their portfolios and share complementary expertise for the long term, while ensuring flexibility in the short term. Broadly speaking, outsourcing models adhere to one of the following three approaches:

  • A full-service approach using either an exclusive or dual-vendor strategy
  • Functional approaches using different strategic vendors for different service areas
  • A more ad hoc, preferred vendor approach where competitive bidding continues

While each approach has its pros and cons, the market is quickly shifting to one of dichotomy, where either functional service provision (FSP) or full-service models are the preferred option among trial sponsors.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
About the author


Daniel Chapple is a Director at Quanticate and oversees a number of functions, including commercial activities. Daniel has over 20 years of experience within the drug development field, with over 15 years spent in the CRO and business process outsourcing sector. He holds a doctorate in Biochemistry, Microbiology, and Immunology from the University of London, UK, is a Fellow of the Institute of Sales Management (FISM), and is a certified ‘green belt’ in Lean Six Sigma.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Key milestone in molded glass: SGD Pharma elevates Type I offering with three tailored product and service solutions

Puteaux Cedex, FRANCE – 23rd March: SGD Pharma, a leading supplier of glass primary packaging in the pharmaceutical industry and global expert in Type I molded glass, introduces an industry first offering of Type I molded glass vials. These market-driven value propositions represent the latest step in SGD Pharma’s ongoing improvements to its product offers and services. According to their specific business and parenteral drug requirements, Pharma and Biotech players would not only benefit from SGD Pharma’s enhanced high quality and reliable products, but also from an extended offer, ranging from Total Cost of Ownership (TCO) optimization to the highest levels of services.
More info >>

White Papers

Contemporary Issues in Comparator Trial Supply

Clinigen CTS

As trial design and execution becomes ever-more complex, initiatives to adapt, increase efficiency and control costs without compromising quality become paramount. Here, Clinigen CTS covers the broad issues and summarises the responses our industry is making in this increasingly demanding landscape.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement